Levulinic acid

CAS No. 123-76-2

Levulinic acid( 4-Oxovaleric acid | Laevulinic acid | β-Acetylpropionic acid )

Catalog No. M20243 CAS No. 123-76-2

Levulinic acid derived from the degradation of cellulose is a precursor for the synthesis of biofuels such as ethyl levulinate.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 28 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG 33 In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Levulinic acid
  • Note
    Research use only, not for human use.
  • Brief Description
    Levulinic acid derived from the degradation of cellulose is a precursor for the synthesis of biofuels such as ethyl levulinate.
  • Description
    Levulinic acid derived from the degradation of cellulose is a precursor for the synthesis of biofuels such as ethyl levulinate.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    4-Oxovaleric acid | Laevulinic acid | β-Acetylpropionic acid
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    Others
  • Research Area
    Cancer
  • Indication
    Transitional Cell Carcinoma of the Bladder

Chemical Information

  • CAS Number
    123-76-2
  • Formula Weight
    116.12
  • Molecular Formula
    C5H8O3
  • Purity
    >98% (HPLC)
  • Solubility
    Water: 100 mg/mL;DMSO: Soluble
  • SMILES
    CC(=O)CCC(O)=O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • Navamepent

    Navamepent (RX-10045) is an analog of resolvin E1 (a dietary-3 polyunsaturated fatty acid metabolite), which has potent anti-inflammatory activity that reduces corneal inflammation, epithelial damage, and accelerates corneal tissue repair.

  • 4-Hydroxymephenytoin

    4-Hydroxymephenytoin is the metabolism of an antiepileptic drug mephenytoin. Mephenytoin is used as a CYP2C19 substrate.

  • SARS-CoV-2 Mpro-IN-9

    SARS-CoV-2 Mpro-IN-9 (compound c7), a nonpeptidic, noncovalent inhibitor of SARS-CoV-2 main protease (Mpro), exhibits potent inhibitory action (IC50 = 0.085 μM) and improved physicochemical and drug metabolism and pharmacokinetics (DMPK) properties.